GSS EU Science Funding Gateway

Proposals should address the following activities:

• Carry out registration (phase III) and/or post-registration studies of health technologies that tackle infectious diseases affecting women and children to demonstrate clinical effectiveness;
• Demonstrate the cost-effectiveness of the health technologies being investigated in the relevant populations and communities;
• Identify the barriers to the uptake of the health technologies under investigation and address them in the proposed studies;
• Develop methods that can ensure translating clinical research results into healthcare policy and practice in a SSA setting. These methods should be broadly applicable to improve patients’ quality of life beyond the specific health technology being investigated;
• Early involvement and regular interaction with policy and decision-makers, including end-users, to ensure adoption of the health technology by health systems in SSA.

This call is restricted to the following diseases: HIV, malaria, tuberculosis, diarrhoeal diseases, bacterial infections (especially those where antimicrobial resistance is an issue), sepsis and lower respiratory tract infections.

The research carried out and the health technologies developed in the study should tackle infections affecting the health of pregnant women and children up to five years of age.

Neither pre-clinical research nor early-stage clinical trials in the context of product development are within the scope of this call.

Proposals should present a sound assessment of the feasibility of the proposed work, in particular as regards the proposed clinical interventions. Realistic plans for recruitment of subjects (as part of the clinical trial plan with projected dates) should be presented and documented by demonstrated success from previous studies. The proposals should justify the choice of populations to be enrolled into the interventions. Relevant determining characteristics (such as socio-economic status) also need to be considered.